Plus Therapeutics Partners with UnitedHealthcare for CNSide®
Plus Therapeutics, Inc. (NASDAQ: PSTV), headquartered in Houston, has made significant strides in the healthcare landscape by forming a national coverage agreement with UnitedHealthcare Insurance Company. This partnership allows the use of the CNSide® Cerebrospinal Fluid Assay for patients suffering from metastatic central nervous system (CNS) cancers, impacting over 51 million individuals across the nation.
Overview of the CNSide® Assay Platform
The CNSide® CSF Assay Platform is a pivotal resource for healthcare professionals, facilitating rapid diagnosis and ongoing treatment monitoring for patients with leptomeningeal metastases. Clinical studies, including nine peer-reviewed publications and the FORESEE clinical trial, have underscored the assay's superior utility in comparison to standard care. The assay has undergone real-world validation, proving its effectiveness in clinical settings.
Results and Efficacy
Since its inception in 2020, over 11,000 CNSide® tests have been performed across more than 120 U.S. cancer institutions. The results have been remarkable, demonstrating a sensitivity of 92% and specificity of 95%. Notably, in 90% of cases, the CNSide® test has influenced treatment decisions, showcasing its critical role in patient management.
Exclusive Availability through CNSide Diagnostics
This essential test is exclusively available through CNSide Diagnostics, LLC, ensuring healthcare professionals can adequately support their patients with cutting-edge diagnostics.
About CNSide Diagnostics, LLC
CNSide Diagnostics is a wholly owned subsidiary of Plus Therapeutics, focused on the development and commercialization of proprietary laboratory-developed tests. These tests, particularly CNSide®, aim to identify tumor cells that metastasize to the central nervous system, especially in carcinoma and melanoma patients. The CNSide® platform empowers healthcare professionals by enabling comprehensive molecular characterization and quantitative analysis of tumor cells and circulating tumor DNA.
About Plus Therapeutics, Inc.
As a clinical-stage pharmaceutical company, Plus Therapeutics is dedicated to developing targeted radiotherapeutics for challenging CNS cancers, aiming to enhance clinical outcomes. By combining innovative image-guided local beta radiation with targeted drug delivery approaches, the company is advancing a robust pipeline designed to tackle complex conditions like recurrent glioblastoma and leptomeningeal metastases.
Plus Therapeutics has successfully built a strategic supply chain through partnerships that facilitate the development and manufacturing of its promising products. This collaboration with UnitedHealthcare marks another milestone in making pivotal cancer treatments accessible across the country.
About UnitedHealthcare Group
UnitedHealth Group (NYSE: UNH) is committed to improving healthcare systems and outcomes, emphasizing the importance of wellness. The company's approach integrates technology and data to enhance care delivery, ensuring patients receive affordable coverage while streamlining the healthcare experience.
Frequently Asked Questions
What is the CNSide® assay and why is it significant?
The CNSide® CSF Assay is a laboratory-developed test that aids in the diagnosis and treatment monitoring of metastatic CNS cancers, emphasizing its role in identifying tumor cells in cerebrospinal fluid.
Who is eligible for the CNSide® testing?
The CNSide® test is designed for patients with leptomeningeal metastases and is available through healthcare professionals across the U.S.
How has CNSide® been received in clinical settings?
With over 11,000 tests performed, CNSide® has demonstrated high sensitivity and specificity, significantly impacting treatment decisions in the majority of cases.
What are the advancements Plus Therapeutics is making?
Plus Therapeutics is advancing targeted therapies for CNS cancers, focusing on clinical-stage products that utilize innovative methods for better patient outcomes.
How can I learn more about Plus Therapeutics?
For more details, visit the Plus Therapeutics website or reach out through their investor contact.
